Mankind Pharma is set to list on May 9 with a premium of Rs 120 apiece according to grey market trends. The company is valued at a price-to-earnings ratio of 30 times FY22 earnings and has a market capitalisation of Rs 44,000 crore. The initial share sale of the company was subscribed 15.32 times with strong interest from QIBs and is the largest IPO so far this year. The company has 25 manufacturing facilities across India, a dedicated in-house R&D centre and a team of over 600 scientists.
FIIs remain net buyers in May, infuse Rs 18,082 crore into Indian equities
Foreign Institutional Investors (FIIs) have shown renewed confidence in Indian equities, becoming net buyers for the second consecutive month. May saw a net inflow of
May 31, 2025